$365.080
0.000 (0.00%)At close
BIO.B News
BIO.B Events
Bio-Rad rises 15.8%
Bio-Rad is up 15.8%, or $38.23 to $280.18.
Bio-Rad sees FY25 non-GAAP, currency-neutral revenue growth of flat to up 1%
Bio-Rad is updating its financial outlook for the full year 2025. The company currently expects non-GAAP, currency-neutral revenue growth of approximately 0 to 1.0 percent versus its prior estimated range of approximately a 1.0 percent decline to 1.5 percent growth. Non-GAAP operating margin is now estimated to be approximately 12.0 to 13.0 percent compared to the company's prior expectation of approximately 10.0 to 12.0 percent.
Bio-Rad reports Q2 adjusted EPS $2.61, consensus $1.75
Reports Q2 revenue $651.6M, consensus $614.29M. Norman Schwartz, Bio-Rad's Chairman and Chief Executive Officer, stated: "In a highly dynamic environment, we delivered solid quarterly results, both in terms of revenue and operating margin, through focused execution and careful expense management. We also completed the acquisition of droplet digital PCR developer Stilla Technologies, effectively expanding our Droplet Digital PCR offering with the recent launch of our QX Continuum system complemented by the QX700 series of acquired instruments."
Bio-Rad expands digital PCR offering with new platforms
Bio-Rad Laboratories announced the launch of four new Droplet Digital PCR platforms, including its QX Continuum system and the QX700 series platforms acquired as part of its recent acquisition of Stilla Technologies. The expanded product portfolio, including over 400K assays, offers a comprehensive line of digital PCR products for life science research and diagnostic applications. Executive VP Jim Barry stated the launch strengthens Bio-Rad's leadership in droplet digital PCR solutions.
Bio-Rad now sees non-GAAP revenue for FY down 1% to up 1.5%
Bio-Rad is updating its financial outlook for the full year 2025. The company currently expects non-GAAP, currency-neutral revenue to range from approximately a 1.0 percent decline to 1.5 percent growth versus its prior revenue growth estimate of approximately 1.5 to 3.5 percent, and an estimated non-GAAP operating margin of approximately 10.0 to 12.0 percent compared to its prior expectation of approximately 13.0 to 13.5 percent.
This page is for research only and is not investment advice. Models can be wrong. Past performance does not guarantee future results.